Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.
About Jean-François Mayol
This author has yet to write their bio.Meanwhile lets just say that we are proud Jean-François Mayol contributed a whooping 16 entries.
Entries by Jean-François Mayol
Geneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]
Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens), its […]
CICON 2019 Sept. 25 – 28, 2019 / Paris / France Elodie Belnoue attending
BIO International Convention 2019 June 3 – 6, 2019 / Philadelphia / USA Madiha Derouazi and Laurence de Schoulepnikoff attending
CIMT Annual Meeting 2019 May 21 – 23, 2019 / Mainz / Germany Matteo Rossi attending
AACR Annual Meeting 2019 March 29 – Apr 3, 2019 / Atlanta / USA Jean-François Mayol attending
European Life Sciences CEO Forum 2019 25 & 26 February 2019 / Zurich / Switzerland Madiha Derouazi and Laurence de Schoulepnikoff attending
Geneva, Switzerland – 12 November 2018 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF […]
Geneva, Switzerland – 19 September 2018 – We are pleased to announce that AMAL Therapeutics is featured in the September edition of BioPharma Dealmakers (Nature Research), outlining the promise of protein-based therapeutics cancer vaccine in oncology. View PDF